clinical trial · NCT07284758
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed/Refractory Multiple MyelomaCemsidomideDexamethasone
brief summary
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
started
Feb 18, 2026
primary completion
Mar 1, 2030
completion
Mar 1, 2030
last updated
Mar 12, 2026
official title
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol